Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology

Natalia Malara, Gyorgy Kovacs, Francesco Bussu, Teresa Ferrazzo, Virginia Garo, Cinzia Raso, Patrizia Cornacchione, Roberto Iezzi*, Luca Tagliaferri

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Although the role of liquid biopsy (LB) to measure minimal residual disease (MRD) in the treatment of epithelial cancer is well known, the biology of the change in the availability of circulating biomarkers arising throughout treatments such as radiotherapy and interventional radio-oncology is less explained. Deep knowledge of how therapeutic effects can influence the biology of the release mechanism at the base of the biomarkers available in the bloodstream is needed for selecting the appropriate treatment-induced tumor circulating biomarker. Combining existing progress in the LB and interventional oncology (IO) fields, a proof of concept is provided, discussing the advantages of the traditional risk assessment of relapsing lesions, limitations, and the timing of detection of the circulating biomarker. The current review aims to help both interventional radiologists and interventional radiation oncologists evaluate the possibility of drawing a tailor-made board of blood-based surveillance markers to reveal subclinical diseases and avoid overtreatment.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCancers
Volume14
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • CTCs
  • cancer
  • ct-DNA
  • interventional oncology
  • liquid biopsy
  • minimal residual disease
  • radiotherapy

Fingerprint

Entra nei temi di ricerca di 'Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology'. Insieme formano una fingerprint unica.

Cita questo